123 related articles for article (PubMed ID: 28159415)
1. Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol.
Xu X; Fang X; Wang J; Zhu H
Bioorg Med Chem Lett; 2017 Mar; 27(5):1325-1328. PubMed ID: 28159415
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.
Wu Y; Min X; Zhuang C; Li J; Yu Z; Dong G; Yao J; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Wei Y; Zhang H; Zhang W; Miao Z
Eur J Med Chem; 2014 Jul; 82():545-51. PubMed ID: 24937186
[TBL] [Abstract][Full Text] [Related]
3. Horner-Wadsworth-Emmons approach to piperlongumine analogues with potent anti-cancer activity.
Han LC; Stanley PA; Wood PJ; Sharma P; Kuruppu AI; Bradshaw TD; Moses JE
Org Biomol Chem; 2016 Aug; 14(31):7585-93. PubMed ID: 27443386
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells.
Kim YH; Yoon YJ; Lee YJ; Kim CH; Lee S; Choung DH; Han DC; Kwon BM
Bioorg Med Chem Lett; 2018 Aug; 28(14):2566-2572. PubMed ID: 29807795
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents.
Zou Y; Yan C; Zhang H; Xu J; Zhang D; Huang Z; Zhang Y
Eur J Med Chem; 2017 Sep; 138():313-319. PubMed ID: 28686911
[TBL] [Abstract][Full Text] [Related]
6. Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.
Zhang Y; Ma H; Wu Y; Wu Z; Yao Z; Zhang W; Zhuang C; Miao Z
Bioorg Med Chem Lett; 2017 Jun; 27(11):2308-2312. PubMed ID: 28434764
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors.
Karki K; Hedrick E; Kasiappan R; Jin UH; Safe S
Cancer Prev Res (Phila); 2017 Aug; 10(8):467-477. PubMed ID: 28673967
[TBL] [Abstract][Full Text] [Related]
8. Piperlongumine derived cyclic sulfonamides (sultams): Synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines.
Lad NP; Kulkarni S; Sharma R; Mascarenhas M; Kulkarni MR; Pandit SS
Eur J Med Chem; 2017 Jan; 126():870-878. PubMed ID: 27987486
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel ROS Inducers: Quinone Derivatives Tethered to Long Hydrocarbon Chains.
Hong Y; Sengupta S; Hur W; Sim T
J Med Chem; 2015 May; 58(9):3739-50. PubMed ID: 25826398
[TBL] [Abstract][Full Text] [Related]
10. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
Chilin A; Conconi MT; Marzaro G; Guiotto A; Urbani L; Tonus F; Parnigotto P
J Med Chem; 2010 Feb; 53(4):1862-6. PubMed ID: 20095624
[TBL] [Abstract][Full Text] [Related]
11. Novel anticancer hybrids from diazen-1-ium-1,2-diolate nitric oxide donor and ROS inducer plumbagin: Design, synthesis and biological evaluations.
Bao N; Ou J; Li N; Zou P; Sun J; Chen L
Eur J Med Chem; 2018 Jun; 154():1-8. PubMed ID: 29772386
[TBL] [Abstract][Full Text] [Related]
12. Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
Zou Y; Zhao D; Yan C; Ji Y; Liu J; Xu J; Lai Y; Tian J; Zhang Y; Huang Z
J Med Chem; 2018 Mar; 61(5):1821-1832. PubMed ID: 29424539
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and bioevaluation of diphyllin glycosides as novel anticancer agents.
Zhao Y; Ni C; Zhang Y; Zhu L
Arch Pharm (Weinheim); 2012 Aug; 345(8):622-8. PubMed ID: 22592997
[TBL] [Abstract][Full Text] [Related]
15. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs.
Adams DJ; Dai M; Pellegrino G; Wagner BK; Stern AM; Shamji AF; Schreiber SL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15115-20. PubMed ID: 22949699
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytotoxic, glutathione-reactive moieties inducing accumulation of reactive oxygen species via glutathione depletion.
Wilke J; Kawamura T; Watanabe N; Osada H; Ziegler S; Waldmann H
Bioorg Med Chem; 2018 May; 26(8):1453-1461. PubMed ID: 29170028
[TBL] [Abstract][Full Text] [Related]
18. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization.
Liu D; Qiu XY; Wu X; Hu DX; Li CY; Yu SB; Pan F; Chen XQ
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):165-172. PubMed ID: 29037814
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer.
Zou P; Xia Y; Ji J; Chen W; Zhang J; Chen X; Rajamanickam V; Chen G; Wang Z; Chen L; Wang Y; Yang S; Liang G
Cancer Lett; 2016 May; 375(1):114-126. PubMed ID: 26963494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
